From: Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Site
Dose (Gy)
Fractions
Lung-peripheral
45
3
Lung-central
50
5
Mediastinal/cervical lymph node
Liver
Spinal/paraspinal
30
Osseous
Abdominal-pelvic metastasis (lymph node/adrenal gland)